Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2331993 | 1.00 | HTR4 (0.43) | HTR4KCNH2DRD2DRD4DRD3 | |
| SCHEMBL2332002 | 1.00 | HTR4 (0.43) | HTR4KCNH2DRD2DRD4DRD3 | |
| SCHEMBL2337922 | 0.90 | HTR4 (0.51) | HTR4KCNH2CACNA1I | |
| SCHEMBL2337661 | 0.89 | HTR4 (0.45) | HTR4KCNH2CACNA1I | |
| SCHEMBL2337664 | 0.89 | HTR4 (0.45) | HTR4KCNH2CACNA1I | |
| SCHEMBL2338462 | 0.88 | HTR4 (0.56) | HTR4KCNH2CACNA1I | |
| SCHEMBL4735415 | 0.84 | HTR4 (0.46) | HTR4KCNH2CACNA1I | |
| SCHEMBL2336140 | 0.80 | HTR4 (0.59) | HTR4KCNH2CACNA1I | |
| SCHEMBL3332945 | 0.80 | HTR4 (0.55) | HTR4KCNH2CACNA1I | |
| SCHEMBL2330306 | 0.79 | HTR4 (0.49) | HTR4KCNH2CACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | claimed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | claimed |
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | KATO TOMOKI | 2010-06-10 | — | — | US | claimed |
| EP-2533780-B1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | ASKAT INC (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-8980922-B2 | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| EP-1713797-B1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1713797-B1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2005073222-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | HTR4 4/4885KCNH2 1052/4885DRD2 106/4885 |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | HTR4, HTR5A, HTR1A | HTR4 1/4885KCNH2 1888/4885DRD2 136/4885 |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | HTR4 4/4885KCNH2 1052/4885DRD2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.